NCT01232556 2019-01-08A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose ChemotherapyPfizerPhase 3 Terminated338 enrolled 15 charts
NCT00867087 2017-12-05Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's LymphomaPfizerPhase 2 Completed64 enrolled 15 charts
NCT01562990 2016-05-23Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second RelapseThe Lymphoma Academic Research OrganisationPhase 1/2 Completed11 enrolled